Key clinical point: Past treatment may affect the risk of death among patients with thoracic malignancies who develop COVID-19.
Major finding: In a multivariate analysis, age over 65 years (P = .018), Eastern Cooperative Oncology Group performance status of 1 (P < .001), prior use of steroids (P = .052), and chemotherapy alone or in combination with immunotherapy (P = .025) were all associated with an increased risk of death.
Study details: Data from the TERAVOLT registry including 400 patients with thoracic cancers and COVID-19.
Disclosures: The TERAVOLT registry is funded, in part, by the International Association for the Study of Lung Cancer. Dr. Horn disclosed relationships with Amgen, AstraZeneca, Bayer, and several other companies.
Horn L et al. ASCO 2020, Abstract LBA111.